[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.191.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 1,793
Citations 0
Editorial
October 16, 2018

Failure of Low-Dose Theophylline to Prevent Exacerbations in Patients With COPD

Author Affiliations
  • 1Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania
  • 2Brigham and Women’s Hospital, Boston, Massachusetts
JAMA. 2018;320(15):1541-1542. doi:10.1001/jama.2018.14295

Exacerbations drive morbidity, mortality, and the costs of care in patients with chronic obstructive pulmonary disease (COPD). Inhaled therapy with long-acting bronchodilators, with or without inhaled glucocorticoids, can help prevent further exacerbations, but some patients continue to experience them despite optimal inhaled medical therapy. These patients are most prone to hospitalization and death with limited pharmacological alternatives to decrease future exacerbations. Long-term macrolide therapy and phosphodiesterase type 4 inhibitors may be options for some patients with recurrent exacerbations, but use of these agents can be cost prohibitive, or cannot be tolerated by all patients. This population represents a large clinical unmet need that requires additional therapeutic options.

×